Arbaclofen Extended-Release for the Treatment of Spasticity in Multiple Sclerosis: A Randomized, Multi-Center, Placebo-Controlled Clinical Trial (Study OS440-3004)
Background: Arbaclofen, the active R-enantiomer of baclofen, a racemic g-aminobutyric acid-B (GABAB) receptor agonist, has been a mainstay...
Arbaclofen Extended-Release for the Treatment of Spasticity in Multiple Sclerosis: An Open-Label Safety Study (Study OS440-3005)
Background: Despite pharmacologic therapy, people with multiple sclerosis (MS) often experience spasticity, which can worsen with longer...
Arbaclofen Extended-Release for Spasticity in Multiple Sclerosis: Responder Analysis of a Phase 3 Randomized, Placebo-Controlled Clinical Study OS440-3004
Background: Arbaclofen is the active R-enantiomer of racemic baclofen. Arbaclofen extended-release (ER) tablets have demonstrated efficacy...
Effects of Extended Photobiomodulation Therapy on Muscle Performance in Persons with Relapsing-Remitting Multiple Sclerosis
Background: Muscle weakness is often reported in persons with multiple sclerosis (PwMS) and can contribute to impaired ambulation....
Improving Communication about Multiple Sclerosis: The MS-Support Decision Aid
Background: Good communication between patients and their health care provider (HCP) is essential for shared decision making (SDM). We...
The Can Do Multiple Sclerosis Outcomes Study: Study Design to Evaluate Program Outcomes
Background: Assessment of self-efficacy has been a focus of Can Do MS programs given prior research showing associations between higher...
Trends in Absence Time and Payments Due to Long- and Short-Term Disability and Workers’ Compensation for Employees with Multiple Sclerosis
Background: Employers offer a variety of absence benefits. It is unknown how benefit design impacts the use of the benefits, the length of...